Microglial activation protects against accumulation of tau aggregates in nondemented individuals with underlying Alzheimer’s disease pathology
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2662-8465
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Microglial activation protects against accumulation of tau aggregates in nondemented individuals with underlying Alzheimer’s disease pathology ; volume:2 ; number:12 ; day:28 ; month:11 ; year:2022 ; pages:1138-1144 ; date:12.2022
Nature aging ; 2, Heft 12 (28.11.2022), 1138-1144, 12.2022
- Creator
-
Pereira, Joana B.
Janelidze, Shorena
Strandberg, Olof
Whelan, Christopher D.
Zetterberg, Henrik
Blennow, Kaj
Palmqvist, Sebastian
Stomrud, Erik
Mattsson-Carlgren, Niklas
Hansson, Oskar
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s43587-022-00310-z
- URN
-
urn:nbn:de:101:1-2023030509294453258634
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:47 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Pereira, Joana B.
- Janelidze, Shorena
- Strandberg, Olof
- Whelan, Christopher D.
- Zetterberg, Henrik
- Blennow, Kaj
- Palmqvist, Sebastian
- Stomrud, Erik
- Mattsson-Carlgren, Niklas
- Hansson, Oskar
- SpringerLink (Online service)
Other Objects (12)
Fluid biomarkers in Alzheimer’s disease – current concepts
Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders
Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease
Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias
Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment
Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease
Salivary Biomarkers for Alzheimer’s Disease and Related Disorders
Second-generation Elecsys cerebrospinal fluid immunoassays aid diagnosis of early Alzheimer’s disease
Cerebral Aβ deposition precedes reduced cerebrospinal fluid and serum Aβ42/Aβ40 ratios in the App NL−F/NL−F knock-in mouse model of Alzheimer’s disease
The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer’s disease
Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer’s and Parkinson’s disease
Fluid biomarkers in Alzheimer’s disease – current concepts
Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders
Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease
Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias
Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment
Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease
Salivary Biomarkers for Alzheimer’s Disease and Related Disorders
Second-generation Elecsys cerebrospinal fluid immunoassays aid diagnosis of early Alzheimer’s disease
Cerebral Aβ deposition precedes reduced cerebrospinal fluid and serum Aβ42/Aβ40 ratios in the App NL−F/NL−F knock-in mouse model of Alzheimer’s disease
The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer’s disease
Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer’s and Parkinson’s disease
Fluid biomarkers in Alzheimer’s disease – current concepts
Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders
Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease
Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias
Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment
Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease
Salivary Biomarkers for Alzheimer’s Disease and Related Disorders
Second-generation Elecsys cerebrospinal fluid immunoassays aid diagnosis of early Alzheimer’s disease
Cerebral Aβ deposition precedes reduced cerebrospinal fluid and serum Aβ42/Aβ40 ratios in the App NL−F/NL−F knock-in mouse model of Alzheimer’s disease
The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer’s disease